Hormones are key actors in gene X environment interactions programming the vulnerability to Parkinson's disease: Glia as a common final pathway

Annals of the New York Academy of Sciences

Volumn 1057, Issue , 2005, Pages 296-318

  Marchetti, Bianca ^a,b   Serra, Pier Andrea ^b   L'Episcopo, Francesca ^a   Tirolo, Cataldo ^a   Caniglia, Salvo ^a   Testa, Nuccio ^a   Cioni, Serena ^c   Gennuso, Florinda ^a   Rocchitta, Gaia ^b   Desole, Maria Speranza ^b   Mazzarino, Maria Clorinda ^c   Miele, Egidio ^b   Morale, Maria Concetta ^a  

^a OASI RESEARCH INSTITUTE IRCCS   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

Author keywords

Dopaminergic neurons; Environment; Genes; Glia; Hormones; Neurodegeneration; Neuroinflammation; Neuroprotection; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ENDOTOXIN; ESTROGEN; GLUCOCORTICOID; HORMONE; NEUROTOXIN;

APOPTOSIS; ASTROCYTE; BRAIN INJURY; CELL COMPARTMENTALIZATION; CELL TYPE; CONFERENCE PAPER; CONVALESCENCE; DEGENERATIVE DISEASE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; EXPOSURE; GENDER; GENETIC SUSCEPTIBILITY; GENOTYPE ENVIRONMENT INTERACTION; GLIA; HEREDITY; HUMAN; IMMUNE SYSTEM; INFLAMMATION; LIFE EVENT; MICROGLIA; NERVE CELL DEGENERATION; NERVE CELL STIMULATION; NERVE REGENERATION; NEUROENDOCRINE SYSTEM; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 32244434803     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1356.023     Document Type: Conference Paper

References (125)

1. AHBON, E. et al. 2000. Prenatal exposure to high levels of glucocorticoids increases the susceptibility of cerebellar granule cells to oxidative stress-induced cell death. Proc. Natl. Acad. Sci. USA 97: 14726-14730.
2. SHANKS, N., S. LAROCQUE & M. MEANEY. 1995. Neonatal endotoxin exposure alters the development of the hypothalamic-pituitary adrenal axis: early illness and later responsivity to stress. J. Neurosci. 15: 376-384.
3. SHANKS, N. et al. 2000. Early-life exposure to endotoxin alters hypothalamic-pituitary-adrenal function and predisposition to inflammation. Proc. Natl. Acad. Sci. USA 97: 5645-5650.
4. MARCHETTI, B. et al. 2002. Exposure to a dysfunctional glucocorticoid receptor from early embryonic life programs the resistance to experimental allergic encephalomyelitis via nitric oxide-induced immunosuppression. J. Immunol. 168: 5848-5859.
5. MARCHETTI, B. et al. 2001. Stress, the immune system and vulnerability to degenerative disorders of the central nervous system in transgenic mice expressing glucocorticoid receptor antisense RNA. Brain Res. Rev. 36: 259-272.
6. PIERPAOLI, W. & H.O. BESEDOVSKY. 1975. Intel dependence of the thymus in programming neuroendocrine functions. Clin. Exp. Immunol. 20: 323-329.
7. PIERPAOLI, W. & E. SORKIN. 1972. Hormones, thymus, and lymphocyte function. Experentia 28: 1385-1389.
8. PIERPAOLI, W. & H.O. BESEDOVSKY. 1975. Interdependece of the thymus in programming neuroendocrine functions. Clin. Exp. Immunol. 20: 323-329.
9. PIERPAOLI, W., H.G. KOOP, J. MULLER & M. KELLER. 1977. Interdependence between neuroendocrine programming and the generation of immune recognition in ontogeny. Cell. Immunol. 29: 16-26.
10. MARCHETTI, B., F. GALLO, Z. FARINELLA & M.C. MORALE. 1996. Unique neuroendocrine-immune (NEI) interactions during pregnancy. In The Physiology of Immunity. M. Kendal & J. Marsh, Eds.: 297-328. CRC Press. London.
11. MORALE, M.C. et al. 2003. Glucocorticoid receptor deficiency increases vulnerability of the nigrostriatal dopaminergic system: critical role of glial nitric oxide. FASEB J. 18: 164-166.
12. McCANN, S.M. et al. 1993. Endocrine aspects of neuroimmunomodulation: methods and overview. In Neurobiology of Cytokines, Part A. Vol. 16, Methods in Neurosciences. E.B. de Souza, Ed.: 187-210. Academic Press. San Diego.
13. PIERPAOLI, W. 1994. The pineal gland as ontogenetic scanner of reproduction, immunity, and aging. The aging clock. Ann. N.Y. Acad. Sci. 741: 46-49.
14. MARCHETTI, B. et al. 1990. Crosstalk communication in the neuroendocrine-reproductive axis: age-dependent alterations in the common communication networks. Ann. N.Y. Acad. Sci. 594: 309-325.
15. MARCHETTI, B., F. GALLO, Z. FARINELLA & M.C. MORALE. 1995. Neuroendocrineimmunology (NEI) at the turn of the century: Towards a molecular understanding of basic mechanisms and implications for reproductive physiopathology. Endocrine 3: 845-861.
16. PIERPAOLI, W. et al. 1997. Circadian melatonin and young-to-old pineal grafting postpone aging and maintain juvenile conditions of reproductive functions in mice and rats. Exp. Gerontol. 32: 587-602.
17. MARCHETTI, B. et al. 1997. Developmental consequences of hypothalamic-pituitary-adrenocortical system disruption: impact on thymus gland maturation and the susceptibility to develop neuroimmune diseases. In Developmental Correlates of Stress System Dysfunction. B. Marchetti, Ed. Dev. Brain Dysfunct. 10: 503-527.
18. MARCHETTI, B. et al. 1990. The neuroendocrine-immune connections in the control of reproductive functions. In Major Advances in Human Female Reproduction E.Y. Adashi and S. Mancuso, Eds.: Serono Symposia Publications from Raven Press. 73: 279-289.
19. BLALOCK, J.E. 1992. Neuroimmunoendocrinology. J.E. Blalock, Ed. Chem. Immunol. 52: Karger. Basel.
20. BLALOCK, J.E. 1994. Shared ligands and receptors as a molecular mechanism for communication between the immune and neuroendocrine systems. Ann. N.Y. Acad. Sci. 741: 292-298.
21. MASON, D. 1991. Genetic variation in the stress response: susceptibility to experimental and implications for human inflammatory disease. Immunol. Today 12: 57-60.
22. MEANEY, M.J. et al. 1996. Early environmental regulation of forebrain glucocorticoid receptor gene expression: implications for the adrenocortical response to stress. Dev. Neurosci. 18: 49-72.
23. MEANEY, M.J. et al. 1993. Basis for the development of individual differences in the hypothalamic-pituitary-adrenal stress response. Cell. Mol. Neurobiol. 13: 321-347.
24. MORALE, M.C. et al. 1995. Disruption of hypothalamic-pituitary adrenocortical system in transgenic animals expressing type II glucocorticoid receptor antisense ribonucleic acid permanently impairs T cell function: effects on T cell trafficking and T cell responsiveness during postnatal development. Endocrinology 136: 3949-3960.
25. MARCHETTI, B. et al. 2005. Glucocorticoid receptor-nitric oxide crosstalk and vulnerability to experimental parkinsonism: pivotal role for glia-neuron interactions. Brain Res. Rev. 48: 302-321.
26. MORALE, M.C. et al. 1991. Blockade of central and peripheral luteinizing hormone-releasing hormone (LHRH) receptors in neonatal rats with a potent LHRH-antagonist inhibits the morphofunctional development of the thymus and maturation of cell-mediated and humoral immune responses. Endocrinology 128: 1073-1085.
27. MARCHETTI, B. et al. 2000. Gender, neuroendocrine-immune interactions, and neuron-glial plasticity: the role of luteinizing hormone releasing hormone (LHRH). Ann. N.Y. Acad. Sci. 917: 678-709.
28. MARCHETTI, B. 1996. The LHRH-astroglial network of signals as a model to study neuroimmune interaction: assessment of messenger systems and transduction mechanisms at cellular and molecular levels. Neuroimmunomodulation 3: 1-27.
29. MARCHETTI, B. 1997. Cross-talk signals in the CNS: the role of neurotrophic and hormonal factors, adhesion molecules, and intercellular signaling agents in a luteinizing hormone-releasing hormone (LHRH)-astroglia interactive network. Trends Biosci. 2: 1-32.
30. MARCHETTI, B. et al. 2001. The hypothalamic-pituitary-gonadal axis and the immune system. In Psychoneuroimmunology, 3rd ed., Vol. 1. R. Ader, D.L. Felton & N. Cohen, Eds.: 363-387. Raven Press. New York.
31. MORALE, M.C. et al. 2001. Special Feature: Neuroendocrine-immune (NEI) circuitry from neuron-glial interactions to function: focus on gender and HPA-HPG interactions on early programming of the NEI system. Immunol. Cell Biol. 79: 400-417.
32. MARCHETTI, B., H. KETTENMANN & W.J. STREIT. 2005. Glia-neuron crosstalk in neuroinflammation, neurodegeneration, and neuroprotection. Brain Res. Rev. 48: 129-489.
33. PEARCE, B. & G.P. WILKIN. 1995. Eicosanoids, purine, and hormone receptors. In Neuroglia. H. Kattenmann & B.R. Ransom, Eds.: 377-386. Oxford University Press. New York.
34. YUNG-TESTAS, I., J.M. RENOIR, G.L. BRUGNARD & E.E. GREENE. 1992. Demonstration of steroid hormones receptor and steroid action in primary cultures of rat glial cells. J. Steroid Biochem. Mol. Biol. 41: 3-8.
35. YUNG-TESTAS, I., J.M. RENOIR, J.M. GSE & E.E. BEAULIEU. 1991. Estrogen inducible progesterone receptors in primary cultures of rat glial cells. Exp. Cell Res. 193: 12-19.
36. CADEPOND, C. et al. 2002. Steroid receptors in various glial cell lines expression and functional studies. Ann. N.Y. Acad. Sci. 973: 484-487.
37. MARCHETTI, B. & M.P. ABBRACCHIO. 2005. To be or not to be (inflammed) is that the question in anti-inflammatory drug therapy of neurodegenerative diseases? Trends Pharmacol. Sci. 26: 517-525.
38. ALOISI, F. 2001. Immune function of microglia. Glia 36: 165-179.
39. BANATI, R., B.J. GEHRMANN, P. SCHUBERT & G.W. KREUTZBERG. 1993. Cytotoxicity of microglia. Glia 7: 111-118.
40. STREIT, W.J. 2002. Physiology and pathophysiology of microglial cell function. In Microglia in the Regenerating and Degenerating Central Nervous System. W.J. Streit, Ed.: 1-15. Springer. New York.
41. STREIT, W.J. 2002. Microglia as neuroprotective: immunocompetent cells of the CNS. Glia 40: 133-139.
42. NICHOLS, N.R. 1999. Glial responses to steroids as markers of brain aging. J. Neurobiol. 40: 485-601.
43. NICHOLS, N.R. et al. 1990. Messenger RNA for glia fibrillary acidic protein is decreased in the rat brain following acute and chronic corticosterone treatment. Mol. Brain Res. 7: 1-7.
44. OLANOW, C.W., A.M. SHAPIRA & Y. AGID. 2003. Neuroprotection for Parkinson's disease: prospects and promises. Ann. Neurol. 53 (Suppl. 3): 51-52.
45. LANGSTON, J.W. et al. 1999. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine exposure. Ann. Neurol. 46: 598-605.
46. JENNER, P. 2003. Oxidative stress in Parkinson's disease. Ann. Neurol. 53: 26-38.
47. JENNER, P. & C.W. OLANOW. 1996. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47: 161-170.
48. McNAUGHT, K.S.P. & P. JENNER. 2000. Extracellular accumulation of nitric oxide, hydrogen peroxide, and glutamate in astrocytic cultures following glutathione depletion, complex I inhibition, and/or lipopolysaccharide-induced activation. Biochem. Pharm. 60: 979-988.
49. HUNOT, S. et al. 1999. Fc epsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, the production of nitric oxide and tumor necrosis factor-alpha in glial cells. J. Neurosci. 19: 3440-3447.
50. HERRERA, A.J. et al. 2000. The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on an opaminergic system. Neurobiol. Dis. 7: 429-447.
51. HIRSCH, B.C., S. HUNOT, P. DAMIER & B. FAUCHEUX. 1998. Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration? Ann. Neurol. 44 (Suppl. 1): 5115-5120.
52. IRAVANI, M.M. et al. 2002. Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience 110: 49-58.
53. GAO, H.M., B. LIU, W. ZHANG & J.S. HONG. 2003. Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol. Sci. Rev. 24: 395-401.
54. GAO, H.M. et al. 2002. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J. Neurochem. 81: 1285-1297.
55. McGEER, P.L. & E.G. McGEER. 2004. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat. Disord. 10 (Suppl. 1): 3-7.
56. HARTMANN, A. et al. 2003. Inflammation and dopaminergic neuronal loss in Parkinson's disease: a complex matter. Exp. Neurol. 184: 561-564.
57. SCHIESS, M. 2003. Nonsteroidal anti-inflammatory drugs protect against Parkinson neurodegeneration: can an NSAID a day keep Parkinson disease away? Arch. Neurol. 60: 1043-1044.
58. CHEN, H. et al. 2003. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson's disease. Arch. Neurol. 60: 1059-1064.
59. WARNER, T.T. & A.H.V. SCHAPIRA. 2003. Genetic and environmental factors in the cause of Parkinson's disease. Ann. Neurol. 53: 16-25.
60. DLUZEN, D.E. & M.W.I. HORSTINK. 2003. Estrogen as a neuroprotectant of nigrostriatal dopaminergic system. Endocrine 21: 67-75.
61. LEVECQUE, C. et al. 2003. Association between Parkinson's disease and polymorphisms in the nNOS and iNOS genes in a community-based case-control study. Hum. Mol. Genet. 12: 79-86.
62. WESTBERG, L. et al. 2004. Association between the estrogen receptor beta gene and age onset of Parkinson's disease. Psychoneuroendocrinology 29: 993-998.
63. BETARBET, R. et al. 2000. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3: 1301-1306.
64. BEZARD, E. et al. 2003. Enriched environment confers resistance to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and cocaine: involvement of dopamine transporter and trophic factors. J. Neurosci. 23: 10999-11007.
65. BEZARD, E. et al. 2000. Adaptive changes in the nigrostriatal pathway in response to increased 1 -methy 1-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration in the mouse. Eur. J. Neurosci. 12: 2892-2900.
66. LING, Z.D. et al. 2004. Combined toxicity of prenatal bacterial endotoxin exposure and post-natal 6-hydroxydopamine in the adult rat midbrain. Neuroscience 124: 619-628.
67. BOCKMAN, D.E. & M.L. KIRBY. 1984. Dependence of thymus development on derivatives of neural crest. Science 223: 498-500.
68. BODEY, B., B. BODEY, JR., S.E. SIEGEL, et al. 1996. Identification of neural crest derived cells within the cellular microenvironment of the thymus employing a library of monoclonal antibodies raised against neuronal tissue. In Vivo 10: 39-48.
69. MAIER, C.C. et al. 1992. Thymocytes express a mRNA that is identical to hypothalamic luteinizing hormone-releasing hormone mRNA. Cell. Mol. Neurobiol. 12: 447-454.
70. PEIFFER, A., M.C. MORALE, N. BARDEN & B. MARCHETTI. 1994. Modulation of glucocorticoid receptor gene expression in the thymus by the sex steroid hormone milieu and correlation with sexual dimorphism of immune response. Endocrine 2: 181-191.
71. 2-adrenergic receptor messenger RNA concentration in the male rat thymus. Mol. Endocrinol. 6: 1513-1522.
72. 2-adrenergic receptor. Am. J. Physiol. 267: 718-731.
73. PÉPIN, M.C., F. POTHIER & N. BARDEN. 1992. Impaired type II glucocorticoid-receptor function in mice bearing antisense RNA transgene. Nature 355: 725-728.
74. STEC, I., N. BARDEN, J.M.H.M. REUL & F. HOLSBOER. 1993. Dexamethazone nonsuppression in transgenic mice expressing antisense RNA to the glucocorticoid receptor. J. Psychiatric Res. 28: 1-5.
75. BARDEN, N. et al. 1997. Endocrine profile and neuroendocrine challenge tests in transgenic mice expressing antisense-RNA against the glucocorticoid receptor. Neuroendocrinology 3: 212-220.
76. DI PAOLO, T., P. BEDARD & A. DUPONT. 1982. Effects of estradiol on intact and denervated striatal dopamine receptors and on dopamine levels: a biochemical and behavioral study. Can. Physiol. Pharmacol. 60: 350-357.
77. LEVESQUE, D., S. GAGNON & T. DI PAOLO. 1989. Striatal dopamine receptor density fluctuates during the rat estrous cycle. Neurosci. Lett. 10: 345-350.
78. BECKER, J.B. 1990. Direct effect of 17beta estradiol on striatum: sex differences in dopamine release. Synapse 5: 157-164.
79. MORISSETTE, M. & T. DI PAOLO. 1993. Effect of chronic estradiol and progesterone treatments of ovariectomized rats on brain dopamine uptake sites. J. Neurochem. 60: 1876-1886.
80. MORISSETTE, M. & T. DI PAOLO. 1993. Sex and estrous cycle variations on rat striatal dopamine uptake sites. Neuroendocrinology 58: 16-22.
81. DLUZEN, D.E. & J.L. McDERMOT. 2002. Estrogen, anti-estrogen, and gender differences in methamphetamine neurotoxicity. Ann. N.Y. Acad. Sci. 965: 136-156.
82. GRANDBOIS, M., M. MORISSETTE, S. CALLIER & T. DI PAOLO. 2000. Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice. Neuroreport 11: 343-346.
83. CALLIER, S., M. MORISSETTE, M. GRANDBOIS & T. DI PAOLO. 2000. Stereospecific prevention by 17-beta estradiol of MPTP-induced dopamine depletion. Synapse 37: 245-251.
84. DLUZEN, D.E. & J.L. MCDERMOTT. 2004. Developmental and genetic influences upon gender differences in methamphetamine-induced nigrostriatal dopaminergic neurotoxicity. Ann. N.Y. Acad. Sci. 1025: 205-220.
85. D'ASTOUS, M., M. MORISSETTE & T. DI PAOLO. 2004. Effect of estrogen receptor agonists treatment in MPTP mice: evidence of neuroprotection by ER alpha agonist. Neuropharmacology 47: 1180-1188.
86. D'ASTOUS, M., T.M. GAJJAR, D.E. DLUZEN, & T. DI PAOLO. 2004. Dopamine transporter as a marker of neuroprotection in methamphetamine-lesioned mice treated acutely with estradiol. Neuroendocrinology 79: 296-304.
87. CREUTZ, L.M. & M.F. KRITZER. 2002. Estrogen receptor beta immunoreactivity in the midbrain of adult rats: regional, subregional, and cellular localization in the A10, A9, and A8 dopamine cell groups. J. Comp. Neurol. 446: 288-300.
88. WANG, L., S. ANDERSSON, M. WARNER & J.A. GUSTAFSSON. 2001. Morphological abnormalities in the brain of estrogen receptor beta knockout mice. Proc. Natl. Acad. Sci. USA 98: 2792-2796.
89. BEHL, C. 2002. Estrogen as a neuroprotective hormone. Nat. Rev. Neurosci. 3: 433-442.
90. DUBAL, D.B. et al. 1999. Estradiol modulates bcl-2 in cerebral ischemia: a potential role for estrogen receptors. J. Neurosci. 19: 6385-6393.
91. DUBAL, D.B. & P.M. WISE. 2001. Neuroprotective effects of estradiol in middle-aged female rats. Endocrinology 142: 43-48.
92. SAWADA, H., M. IBI & T. KIHARA. 1998. Estradiol protects mesencephalic dopaminergic neurons from oxidative stress-induced neuronal death. J. Neurosci. Res. 54: 707-719.
93. SAWADA, H. et al. 2002. Estradiol protects dopminergic neurons in a MPP+Parkinson's disease model. Neuropharmacology 42: 1056-1064.
94. AZCOITIA, D. et al. 2001. Astroglia play a key role in the neuroprotective actions of estrogen. Prog. Brain Res. 132: 469-478.
95. GARCIA-OVEJERO, D. et al. 2005. Glia-neuron crosstalk in the neuroprotective mechanisms of sex steroid hormones. Brain Res. Rev. 48: 2130-2142.
96. TAKESHIMA, T., J.M. JOHNSTON & J.W. COMMISSIONG. 1994. Mesencephalic type 1 astrocytes rescue dopaminergic neurons from death induced by serum deprivation. J. Neurosci. 14: 4769-4779.
97. GALLO, M.C. et al. 2000. Basic fibroblast growth factor (bFGF) acts on both neurons and glia to mediate the neurotrophic effects of astrocytes on LHRH neurons in culture. Synapse 36: 233-253.
98. GALLO, M.C. et al. 2000. Basic fibroblast growth factor (bFGF) priming increases the response of LHRH neurons to neurotrophic factors. J. Neuroendocrinol. 12: 941-959.
99. DRINGEN, R., J. GUTTERER & J. HIRRLINGER. 2000. Glutathione metabolism in brain. Metabolic interaction between astrocytes and neurons in the defense against reactive oxygen species. Eur. J. Biochem. 267: 4912-4916.
100. PARK, C., H. ZHANG & G.E. GIBSON. 2001. Co-culture with astrocytes or microglia protects metabolically impaired neurons. Mech. Ageing Dev. 123: 21-27.
101. McNAUGHT, K.S.P. & P. JENNER. 1999. Altered glial function causes neuronal death and increases neuronal susceptibility to 1-methyl-4- phenylpyridinium- and 6-hydroxydopamine-induced toxicity in astrocytic/ventral mesencephalic co-cultures. J. Neurochem. 73: 2469.
102. SMEYNE, O., O. GOLOUBEVA & R.J. SMEYNE. 2001. Strain-dependent susceptibility to MPTP and MPTP(+)-induced parkinsonism is determined by glia. Glia 34: 73-80.
103. DI MONTE, D.A. & J.W. LANGSTON. 1995. Idiopathic and 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. In Neuroglia. H. Kettenmann & B.R. Ransom, Eds.: 997-989. New York. Oxford University Press.
104. GEGG, M.E. et al. 2003. Differential effect of nitric oxide on glutathione metabolism and mitochondrial function of astrocytes and neurones: implications for neuroprotection/neurodegeneration? J. Neurochem. 86: 228-237.
105. GENNUSO, F. et al. 2004. Bilirubin protects astrocytes from its own toxicity inducing upregulation and translocation of multigrug resistance-associated protein 1 (Mrp 1). Proc. Natl. Acad. Sci. USA 101: 2470-2475.
106. SACEDON, R. et al. 1999. Partial blockade of T cell differentiation and marked alteration of the thymic microenvironment in transgenic mice with a dysfunctional glucocorticoid receptor function. J. Neuroimmunol. 98: 157-167.
107. + regulatory T cell compartment. J. Immunol. 173: 2227-2230.
108. BRUCE-KELLER, A.J. et al. 2000. Anti-inflammatory effects of estrogen on microglial activation. Endocrinology 141: 3646-3656.
109. DREW, P.D. & J.A. CHAVIS. 2000. Female sex steroids: effects upon microglial cell activation. J. Neuroimmunol. 111: 77-85.
110. VEGETO, E. et al. 2003. Estrogen receptor-alpha mediates the brain anti-inflammatory activity of estradiol. Proc. Natl. Acad. Sci. USA 100: 9614-9619.
111. DODEL, R.C., Y. DU & K.R. BALES. 1999. Sodium salicylate and 17 beta estradiol attenuate nuclera transcription factor NF-κB translocation in cultured rat astroglia cultures following exposure to amyloid beta (1-40) and lipopolisaccharide. J. Neurochem. 73: 1453-1460.
112. MORALE, M.C. et al. 2005. Estrogens, neurinflammation, and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration. Neuroscience. In press.
113. LONG, J.M. et al. 1998. Stereological analysis of astrocyte and microglia in the aging mouse hippocampus. Neurobiol. Aging 19: 497-503.
114. LUQUIN, S., F. NAFTOLIN & L.M. GARCIA-SEGURA. 1993. Natural fluctuation and gonadal hormone regulation of astrocyte immunoreactivity in dentate gyrus. J. Neurobiol. 24: 913-924.
115. LEI, D.-L. et al. 2003. Effects of estrogen and raloxifene on neuroglia number and morphology in the hippocampus of aged female mice. Neuroscience 121: 659-666.
116. MOUTON, P.R. 2002. Age and gender affect microglia and astrocyte number in the brain of mice. Brain Res. 956: 30-36.
117. GARCIA-OVEJERO, D., S. VEIGA, L.M. GARCIA-SEGURA & L.L. DONCARLOS. 2002. Glial expression of estrogen and androgen receptors after rat brain injury. J. Comp. Neurol. 450: 256-271.
118. MILLER, D.B., S.F. ALI, J.P. O'CALLAGHAN & S.C. LAW. 1998. The impact of gender and estrogen on striatal dopamine neurotoxicity. Ann. N.Y. Acad. Sci. 844: 153-165.
119. GARCIA-SEGURA, L.M. et al. 1999. Role of astroglia in estrogen regulation of synaptic plasticty and brain repair. J. Neurobiol. 40: 574-584.
120. LIBERTO, C.M. et al. 2004. Pro-regenerative properties of cytokine-activated astrocytes. J. Neurochem. 89: 1092-1100.
121. EKDAL, J.H. et al. 2003. Inflammation is detrimental for neurogenesis in the adult brain. Proc. Natl. Acad. Sci. USA 100: 13632-13637.
122. FAULKNER, J.R. 2004. Reactive astrocytes protect tissue and preserve function after spinal cord injury. J. Neurosci. 24: 2143-2155.
123. MONJE, M.L., H. TODA & T.D. PALMER. 2003. Inflammatory blockade restores adult hippocampal neurogenesis. Science 302: 1760-1765.
124. LEHNARDT, S. et al. 2003. Activation of innate immunity in the CNS triggers neurode-generation through a Toll-like receptor 4-dependent pathway. Proc. Natl. Acad. Sci. USA 100: 8514-8519.
125. LONARD, D.M. & C.L. SMITH. 2002. Molecular perspectives on selective estrogen receptor modulators (SERMs): progress in understanding their tissue-specific agonist and antagonist actions. Steroids 67: 15-24.